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Late outcomes of balloon angioplasty and
angioplasty with selective stenting for superficial
femoral-popliteal disease are equivalent
Bao-Ngoc Nguyen, MD, Mark F. Conrad, MD, Julie M. Guest, BS, Lauren Hackney, BS,
Viendra I. Patel, MD, Christopher J. Kwolek, MD, and Richard P. Cambria, MD, Boston, Mass
Objective: Several trials have reported early superior patency of stenting over isolated angioplasty (plain old balloon
angioplasty [POBA]) for infra-inguinal occlusive disease, yet long-term data are sparse. The purpose of this study was to
contrast long-term clinical outcomes and costs of angioplasty alone vs angioplasty with selective stenting in the treatment
of femoropopliteal occlusive disease.
Methods: Patients undergoing primary endovascular treatments of the native femoropopliteal arteries from 2002 to 2009
were divided into two groups, POBA alone or stenting based on final treatment received at their index procedure. Study
end points included actuarial 5-year primary patency (using strict criteria of any hemodynamic deterioration or return of
symptoms), 5-year limb salvage, and 5-year survival and hospital costs.
Results:Eight hundred twenty-four primary procedures were performed during the study interval; 517 (63%) were POBA
and 307 (37%) were stenting. The mean follow-up duration was 33 months (range, 0-98 months). The indication for
intervention in the stenting group was claudication in 71% of the patients, whereas the remaining 29% had critical limb
ischemia (CLI). In the POBA cohort, the indication for treatment was claudication in 59% of the patients and CLI in the
remaining 41%. A higher percentage of POBA lesions were TransAtlantic Inter-Society Consensus (TASC) II A&Bwhen
compared to stenting (91% POBA vs 73% stenting; P < .001). There was no difference in overall 5-year primary patency
(POBA 36%  3%; stenting 41%  4%; P  .31), nor was there a difference in patients with claudication (POBA 42% 
4%; stenting 45%  4%; P  .8). In patients with CLI, the 4-year primary patency was 27%  5% (POBA) vs 36%  8%
(stenting), P  .22; the 4-year limb salvage was 80%  4% (POBA) vs 90%  5% (stenting), P  .18. There was no
difference in survival between the two groups (claudication: 83%  3% POBA vs 84%  4% stenting at 5 years (P  .65),
CLI: 44%  4% POBA vs 49%  6% stenting at 4 years (P  .40). Subgroup analysis by lesion anatomy showed similar
primary patency between POBA and stenting for TASC II A & B lesions, while the primary patency was significantly
higher at 5 years after stenting of TASC II C & D lesions (34%  6% vs 12%  9%; P < .05). Stenting increased the
procedural cost by 57% when compared to POBA (P < .001) regardless of treatment indication. In addition, stenting
added 45% (P < .001) to the overall hospital cost of patients treated for claudication.
Conclusion: Stenting resulted in equivalent long-term outcomes compared to POBA when stratified by indications.
However, stenting yielded statistically better primary patency in patients with TASC II C & D lesions. The lack of
improved clinical outcomes and significantly higher cost of stenting supports a posture of selective use of stents (especially
in TASC II A & B) in the endovascular treatment of femoropopliteal occlusive disease. ( J Vasc Surg 2011;54:1051-7.)
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cIt is common for clinical studies detailing the endovas-
cular treatment of lower extremity occlusive disease to
begin with the caveat that surgical bypass remains the gold
standard, but recent randomized trial data have provided a
balanced perspective, at least for patients with critical limb
ischemia (CLI).1 Primarily influenced by a high-risk co-
morbidity profile, life expectancy limitations seen in pa-
tients with CLI,2 and the sobering objective data regarding
the morbidity of leg bypass surgery,3 our approach to
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doi:10.1016/j.jvs.2011.03.283hronic lower extremity ischemia has gravitated toward an
angioplasty first” posture for the majority of patients who
equire leg revascularization.4,5 Prior studies have docu-
ented an approximate 20% reintervention rate, and a 5%
surgical bailout rate” coincident with this posture.4 In the
ourse of this experience, we have used infra-inguinal stents
electively and recorded a primary stent application of
20% in this population.4 While corroborative literature
or this approach exists,6-8 other reports, including ran-
omized trial data, have shown improved primary patency
ith stenting in the short-term.9-11
There are conflicting data in the literature regarding the
uccess of routine stenting vs selective stenting for lesions of
he femoropopliteal arterial segment. Several single-center
xperiences did not support routine stenting because it
ailed to reduce long-term re-stenosis,6-8 and a randomized
ontrolled trial by Krankenberg et al12 showed that for
hort lesions, there was no additional patency benefit of
tenting over plain old balloon angioplasty (POBA). In
ontrast, two major randomized controlled trials found
uperior 2-year primary patency with stenting for moderate
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October 20111052 Nguyen et alto long superficial femoral arterial lesions.9-11 Yet, there is a
paucity of data in the literature regarding the long-term
results of stenting beyond 2 years.13 Indeed, in-stent re-
stenosis remains a major hurdle that prevents the transla-
tion of immediate technical success and short-term benefit
of stenting into long-term patency. Even less has been
written about the cost-effectiveness of stenting vs POBA,
an issue of increasing concern given the proliferation of
endovascular devices and increase in volume of proce-
dures for leg revascularization over the past decade.14-19
This study reviews our 8-year, multidisciplinary, single-
institution experience with the endovascular treatment
of chronic lower extremity ischemia with specific empha-
sis on the long-term clinical outcomes (primary patency,
limb salvage, and survival) of POBA vs stenting of the
femoropopliteal arterial segment. In addition to long-
term outcomes, early cost differences between the two
treatment modalities were evaluated.
METHODS
Patients. All patients who underwent endovascular
treatment for native femoropopliteal arterial occlusive dis-
ease between March 2002 and December 2009 were iden-
tified. The patients were treated for the first time with
POBA/stenting at theMassachusetts General Hospital by a
multidisciplinary group of nine different operators, which
included vascular surgeons, interventional cardiologists,
and interventional vascular medicine specialists, creden-
tialed to perform endovascular procedures. There was no
consensus position about the application of stenting. Ex-
clusive criteria included acute limb-threatened ischemia,
interventions on failing bypass grafts, combined endovas-
cular and surgical endarterectomy, any reintervention, or
those combined with inflow procedures such as iliac artery
stenting. All stents used were bare metal and self-expandable;
cases that involved covered stents were excluded. Cases
with mechanical thrombectomy, atherectomy, and/or in-
fusion of thrombolytic agents were also excluded.
Patients were stratified into POBA (angioplasty only)
and stenting cohorts. The decision to stent was left to the
discretion of the attending interventionalist. Individual
limbs were counted separately so that bilateral procedures
on the same patient were counted as two entries. The study
population included only those patients who were treated
in the cardiac catheterization laboratory in order to avoid
cost differences due to different settings. This study was
approved by the institutional review board of the Massa-
chusetts General Hospital.
Demographic and clinical data were obtained for each
patient. Renal insufficiency was defined as serum creatinine
1.5 mg/dL. Indications for treatment were divided into
claudication (Rutherford classification 1-3) and CLI
(Rutherford 4-6) which included rest pain or tissue loss.20
Anatomic features of the lesions were retrospectively re-
corded based on operative notes and arteriograms accord-
ing to the TransAtlantic Inter-Society Consensus (TASC) cI classification.21 The TASC II classification for femoro-
opliteal occlusive disease includes:
● TASC II A: A single stenosis 10 cm or a single
occlusion 5-cm long.
● TASC II B: Multiple lesions each5 cm, single steno-
sis/occlusion 15 cm not involving the infragenicu-
late popliteal artery, single/multiple lesions in the
absence of continuous tibial vessels, heavily calcified
occlusion 5 cm, or a single popliteal stenosis.
● TASC II C: Multiple stenoses/occlusions totaling
15 cm, recurrent stenoses/occlusions that need
treatment after two endovascular interventions.
● TASC II D: Chronic total occlusions of common
femoral artery or superficial femoral artery (20 cm,
involving the popliteal artery), chronic total occlusion
of the popliteal artery and proximal trifurcation vessels.
This study excluded reintervention procedures; there-
ore, TASC II C & D lesions were all long chronic steno-
es/occlusions.
Postprocedure follow-up. Patients were routinely
ollowed at 4 to 6 weeks after the initial intervention and
very 3 to 6months afterward. Resolution and/or return of
ymptoms were recorded. Routine objective data included
ulse examinations and ankle brachial index (ABI). Pulse
olume recording and/or arterial duplex were obtained at
he discretion of the operators.
End points. The average follow-up was 33 months
range, 0-98 months). The primary end point for the study
as long-term primary patency. Secondary end points in-
luded limb salvage, overall survival, and procedural costs
etween the two cohorts. Failure of primary patency was
efined by the presence of one or more of the following
riterion: (1) decrease in ABI of more than 0.10, (2)
e-stenosis of the treated lesions of 50% via arterial du-
lex, and (3) recurrence of symptoms regardless of whether
urther interventions were performed. Failure of limb sal-
age was defined as any major amputation and excluded toe
nd forefoot amputations. Limb salvage data were calcu-
ated only for patients with CLI. Survival was determined
hrough a review of the computerized records of the Mas-
achusetts General Hospital and the social security death
ndex when necessary. Procedure and hospital costs were
rovided by the hospital accounting department based on
he medical record number, date of procedure, and dura-
ion for the index admission. Cost figures are presented as
ncremental percentage difference between cohorts rather
han absolute numbers because of institutional policy.
Statistical analysis. Comparison of demographic and
isk factors between POBA and stenting were performed
sing 2 and t tests as appropriate. Kaplan-Meier life tables
ith Mantel-Cox log-rank univariate analysis were used to
dentify predictors of failure of primary patency. Relative risk
nd confidence intervals (CIs) were determined using a mul-
ivariate Cox proportional hazards model for all independent
ariables, including hypertension, heart disease, diabetes,
hronic renal insufficiency, dialysis, smoking, hyperlipidemia,
ongestive heart failure, treatment indication (claudication vs
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Volume 54, Number 4 Nguyen et al 1053CLI), anatomic features (TASC II A&B vs TASC IIC&D),
and treatment modality (POBA vs stenting). Actuarial pri-
mary patency, limb salvage, and survival analysis were per-
formed using Kaplan-Meier life methods with log-rank anal-
ysis to identify differences between groups. Costs were
analyzed using the t test. Statistical significance was defined as
P .05.
RESULTS
There were a total of 824 primary procedures per-
formed in the femoropopliteal arterial segment of 733
patients during the study period; 517 patients (63%) were
treated with POBA and 307 patients (37%) received stents.
Patient demographics, risk factors, and TASC II lesion
classifications are summarized in Table I. There were sig-
nificantly higher incidences of smoking and hyperlipidemia
in the stenting group while dialysis dependence was more
frequent in the POBA cohort. In the POBA group, the
indication for intervention was split almost evenly between
claudication and CLI (59% vs 41%, respectively). However,
in the stenting group, the majority of patients (71%) were
treated for claudication and only 29% had CLI (P  .01).
Most patients undergoing POBA had TASC II A & B
lesions (91%) and only 73% of the stenting cohort had
TASC II A & B lesions.
Themean duration of follow-up was 33months (range,
0-98 months). Sixty-five percent of patients were followed
for 3 years and 20% had4-year surveillance. There was no
difference in overall actuarial 5-year primary patency be-
tween the two cohorts (36%  3% POBA vs 41%  4%
stenting; P  .30). Multivariate analysis showed that both
Table I. Demographic and clinical data
Total
(%)
POBA
(%)
Stenting
(%) P value
Patients 824 517 (63) 307 (37)
Male gender 530 336 (65) 194 (63) .61
Indications
Claudication 524 306 (59) 218 (71) .01
Critical limb ischemia 300 211 (41) 89 (29)
Risk factors
Hypertension 661 473 (91) 188 (61) .51
Heart disease 506 306 (59) 200 (65) .14
Diabetes 393 260 (50) 133 (43) .74
CRI 220 150 (29) 70 (23) .32
Dialysis 60 48 (9.2) 12 (3.8) .01
Current smoker 150 78 (15) 72 (23) .02
Previous smoker 610 363 (70) 247 (80) .01
Hyperlipidemia 657 391 (75) 266 (86) .01
CHF 162 110 (21) 52 (17) .31
TASC classification .001
TASC A 208 149 (29) 59 (19)
TASC B 486 318 (62) 168 (55)
TASC C 85 33 (6.4) 52 (17)
TASC D 48 19 (3.7) 29 (9.4)
CHF, Congestive heart failure; CRI, chronic renal insufficiency; POBA, plain
old balloon angioplasty; TASC, TransAtlantic Inter-Society Consensus.
(Cr 1.5 mg/dL.)CLI (coefficient 1.63; CI, 1.27-2.10; P  .01) and TASC tI C & D classification (coefficient 1.49; CI, 1.12-1.97;
 .01) were negative predictors of primary patency. The
se of POBA vs stenting did not affect primary patency on
nivariate or multivariate analysis (Table II).
Because treatment indication was shown to significantly
nfluence primary patency, long-term outcomes were ana-
yzed for claudication and CLI separately. There was no
ifference in 5-year primary patency between POBA and
tenting among the patients with claudication (42%  4% vs
5%  4%; P  .80; Fig 1, A), nor was there a difference in
-year primary patency in patientswithCLI (27%5%POBA
s 36%  8% stenting; P  .22; Fig 1, B). The 4-year limb
alvage for patientswithCLIwas 80%4% (POBA) vs 90%
% (stenting), P .18 (Fig 1, C). The 5-year survival for the
ntire cohort was 76%. The 5-year survival was similar be-
ween the two cohorts for claudication (83%  3% POBA vs
4%  4% stenting, P  .65) and CLI (37%  4% POBA vs
6%  7% stenting; P  .40; Supplementary Figs 1 and 2,
nline only).
When the cohorts were stratified by TASC II classifica-
ion, there were no significant differences between POBA and
tenting for TASC II A&B lesions. Five-year primary patency
as similar (37% 3%POBAvs 43% 5% stenting;P .21).
ive-year limb salvage was 81%  4% (POBA) vs 86%  9%
stenting), P .07. Five-year survival was 65% 3% (POBA)
s 71% 4% (stenting), P .16 (Table III).
In contrast, for TASC II C & D lesions, stenting
ffered significantly higher short-term and long-term pri-
ary patency compared to POBA (54% 5% vs 30 7% at
year, 34%  6% vs 12%  9% at 5 years; P  .05; Fig 2).
his difference did not translate into a difference in 2-year
imb salvage between the two cohorts (stenting 90% 7%;
OBA 77% 9%; P .95). There was also no difference in
-year survival between the two cohorts (stenting 78% 
%; POBA 82%  6%; P  .69).
The procedural cost was 57% higher in patients who
eceived stents when compared to POBA (P  .01), but
able II. Multivariate analysis of predictive variables of
rimary patency
HR 95% CI P value
ypertension 0.87 0.56-1.37 .56
eart disease 0.92 0.72-1.17 .48
iabetes 1.20 0.96-1.52 .11
RI 0.87 0.65-1.16 .35
ialysis 1.46 0.92-2.31 .11
urrent smoker 1.19 0.90-1.57 .22
revious smoker 0.87 0.66-1.14 .30
yperlipidemia 1.00 0.74-1.35 .98
HF 1.08 0.80-1.47 .61
ASC II C & D 1.49 1.12-1.97 .01
LI 1.63 1.27-2.10 .01
OBA 1.02 0.80-1.29 .87
HF, Congestive heart failure; CI, confidence interval; CLI, critical limb
schemia; CRI, chronic renal insufficiency; HR, hazard ratio; POBA, plain
ld balloon angioplasty; TASC, TransAtlantic Inter-Society Consensus.
Cr 1.5 mg/dL.)here was no difference in overall hospital cost (16% higher
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indications, stenting for claudication added 59% (P  .01)
to the procedural cost and 45% (P  .01) to the hospital
cost of POBA. For CLI, stenting added 60% (P  .01) to
the procedural cost and 27% (P  .06) to the hospital cost
Fig 1. A, Kaplan-Meier curves of primary patency for p
patients with claudication. SE did not exceed 10% at 5 ye
selective stenting in patients with critical limb ischemia.
limb salvage for POBA vs selective stenting in patients wof POBA. pISCUSSION
To the best of our knowledge, this study represents one
f the largest single-center experiences with the endovas-
ular treatment of atherosclerotic disease of the femoro-
old balloon angioplasty (POBA) vs selective stenting in
, Kaplan-Meier curves of primary patency for POBA vs
d not exceed 10% at 4 years. C, Kaplan-Meier curves of
itical limb ischemia. SE did not exceed 10% at 4 years.lain
ars. B
SE diopliteal segment with long-term follow-up. As perhaps
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Volume 54, Number 4 Nguyen et al 1055intuitively expected, our data show that clinical indication
(specifically CLI) and lesion extent (TASC II C & D) are
the two major independent predictors of failure of primary
patency. However, unlike recent prospective trials,9,10
stenting did not improve primary patency over POBA
regardless of clinical presentation. When the cohort was
stratified by lesion extent, there was no difference in out-
comes with TASC II A & B lesions, whereas patients who
received a stent for TASC II C&D lesions had significantly
improved primary patency rates; although both were low
(23% POBA vs 34% stenting at 4 years). The improved rate
Table III. Long-term outcomes of TASC II A & B
lesions
POBA Stenting P value
3-year
Primary patency 46  3% 55  4% .21
Limb salvage (for CLI) 83  3% 94  4% .07
Survival 75  2% 80  3% .16
5-year
Primary patency 37  3% 43  5% .21
Limb salvage (for CLI) 81  4% 86  9% .07
Survival 65  3% 71  4% .16
CLI, Critical limb ischemia; POBA, plain old balloon angioplasty; TASC,
TransAtlantic Inter-Society Consensus.
Fig 2. Kaplan-Meier curves of primary patency for plain old bal-
loon angioplasty (POBA) vs selective stenting in patients with
TransAtlantic Inter-Society Consensus (TASC) II C & D lesions.
SE did not exceed 10% at 4 years.of primary patency achieved with stenting for TASC II C& plesions did not translate to better limb salvage in patients
ith CLI.
One of the most difficult and controversial aspects of
valuating the efficacy or durability of endovascular proce-
ures in the femoropopliteal segment remains the determi-
ation of primary patency. Unlike infrainguinal bypass
rafts, which have accepted reporting standards,22 patency
fter angioplasty is often determined by clinical or hemo-
ynamic factors or a combination of both and such defini-
ions vary across studies making direct comparison difficult.
n the current study, there was a lack of uniformmethods of
ollow-up among operators such that we considered a
ecrease of ABI of 0.10, return of symptoms, or re-stenosis
f more than 50% via arterial duplex scan to be a failure of
rimary patency regardless of whether a reintervention was
erformed.
There are three recent randomized controlled trials
hat compared primary stenting to POBA for femoropop-
iteal disease in the short-term.9-12 In the Femoral Artery
tenting Trial (FAST), patients with claudication and
ASC II A lesions (average length 4.5 cm) were random-
zed between angioplasty and stenting. The authors
howed no difference in 1-year primary patency between
he two groups (61.4% POBA and 68.3% stenting, P 
38).12 These results are similar to the current study which
howed a 1-year primary patency of 64% to 67% in patients
ith TASC II A & B lesions and 67% for patients with
laudication (Fig 1, A). These comparable early results are
olstered by the fact that patient population of the current
tudy could be considered at higher risk for failure than the
AST population, which included only TASC II A lesions
nd excluded patients on dialysis (7% of the current co-
ort). Indeed, when TASC II A lesions were considered
lone in the current study, the 1-year primary patency rate
as 68.4% for the entire cohort.
The Randomized Study Comparing the Edwards Self-
xpanding Lifestent versus Angioplasty Alone In Lesions
nvolving The SFA and/or Proximal Popliteal Artery
RESILIENT) trial again only included patients with clau-
ication and TASC II A lesions (average length 6.4-7.1
m).9 In contrast to the FAST and current study, the
-year duplex ultrasound-derived primary patency in the
ESILIENT trial favored stenting (81% stenting vs
6.7% POBA; P  .0001). However, the acute lesion
uccess rate (30% residual stenosis) was significantly
ower in the POBA group (83.9% POBA vs 95.8% stent-
ng; P  .01), and 40% of patients who were initially
andomized to angioplasty alone were crossed over to
he stenting group as a bailout and were considered
mmediate failures of primary patency. This resulted in a
arge bias against POBA in the intention-to-treat analy-
is. When these patients were excluded, the 1-year pri-
ary patency for POBA was 61.5%, comparable to the
AST and current study. Nevertheless, the 80% 1-year
rimary patency in the stenting cohort is remarkable and
hows that early excellent results can be achieved with
roperly selected patients.
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October 20111056 Nguyen et alThe ABSOLUTE trial randomized patients with Ruth-
erford class 3–5 disease (85% claudication, 13% CLI) and
TASC II A&B lesions (average length 12-13 cm) to POBA
vs primary stenting and reported a 1-year primary pat-
ency of 63% for stenting vs 37% for POBA.10 As in the
RESILIENT trial, 32% of the POBA lesions were treated
with immediate secondary stenting for persistent dissection
or residual stenosis. This stent bailout rate is similar to the
percentage of stents (37%) placed in the current study.
Indeed, the 1-year primary patency of successful POBA in
both the ABSOLUTE and RESILIENT trials lends sup-
port to the selective approach to stenting in the femoro-
popliteal segment.
In this series, the overall 5-year primary patency was
35.4% with no difference seen between the stenting and
POBA cohorts (P  .33). This outcome compares favor-
ably to that of Kudo et al23 wherein primary patency was
31.4% at 5 years in patients with CLI. Although the 4-year
primary patency for patients in our study with CLI was 27%
in the POBA cohort and 36% in the stenting cohort, the
4-year limb salvage rate of 80% to 90% is comparable to that
of femorotibial bypass with autogenous vein and certainly
better than with prosthetic conduit.24,25 This phenomenon
has been supported by others who found that despite
inferior rates of primary patency, infra-inguinal percutane-
ous transluminal angioplasty/stent leads to limb salvage
rates that range from 80% to 95% at 1 to 3 years.23,26,27
Lesion severity (as determined by the TASC II classifi-
cation) has been shown to predict outcome after endovas-
cular treatment of femoropopliteal lesions.21 In the current
study, there was no difference in long-term primary patency
for POBA or stenting of TASC II A/B lesions but stenting
led to improved patency in the TASC II C&D lesions (P
.01). This difference was due to early failure of the POBA
cohort that had a primary patency of 30% at 1 year (Fig 2).
The primary patency curve for the stented TASC II C & D
patients is similar to several single institution studies in the
literature. Dearing et al28 reported a 2-year patency rate of
36% in TASC II C & D patients who were treated with
primary stenting while Baril et al29 reported a 2-year pa-
tency of 27.5% in TASC II C & D patients.
There have been three meta-analyses that have at-
tempted to address the question of the utility of primary
stenting over POBA with selective stenting in the femoro-
popliteal segment. Muradin et al30 published a review of 19
studies from 1993 to 2000 that included 923 POBAs and
473 stent placements. They reported a 3-year combined
patency rate of 61% for POBA in patients with stenoses and
43% to 48% for occlusions while the 3-year patency rate for
stenting was 63% and 66% for stenoses and occlusions,
respectively. They concluded that stenting may be more
favorable for patients with severe disease,30 a posture that is
supported by the current study. Two recent reviews of
more contemporary studies have failed to demonstrate
an increase in primary patency with stent placement and
report 2-year primary patency rates of 25% to 77% for
POBA and 46% to 87% for stenting with no difference in Oarget revascularization (which averaged 20%) between
he two treatments.6,31
Little has been written regarding the cost ramification
f primary stenting of the femoropopliteal segment. In the
urrent study, stenting resulted in a 57% increase in proce-
ural cost and a 16% increase in hospital cost when com-
ared to POBA. Muradin et al30 ran a comparison of
rocedural costs of endovascular therapy to surgical bypass
nd concluded that if a device (stent/balloon) costs $4000,
hen the 5-year patency would need to be 24% to 46% for
he device cost to be comparable to open bypass for a
atient with CLI. If the same device was used in a patient
ith claudication, the 5-year patency would need to be 69%
o 85%.30 As cost containment has become an important
omponent of health care delivery, the use of selective
tenting in the femoropopliteal segment seems to fill this
ole without compromising outcome in most lesions.
owever, as interventions are required to maintain patency
nd limb salvage (as in TASC II C & D), primary stenting
r surgical bypass may be a better option in appropriate
atients.
The major limiting factor of the current study remains
ts retrospective nature; continued prospective analysis of
OBA vs stenting with longer follow-up is necessary. The
womajor predictors of failure of primary patency were CLI
nd TASC classification. In order to address this, subgroup
nalysis was performed. Such stratification led to smaller
umbers and risks a type II error; especially in the TASC II
& D cohort. The fact that all patients were treated at a
ingle institution opens the potential for referral/selection
ias based on the current practice of the group. Finally,
here was no uniform follow-up protocol in place; different
perators utilized noninvasive studies such as pulse volume
ecordings, ABIs, and duplex scans in various schemes
ecessitating a broad and stringent definition of primary
atency.
ONCLUSION
In prior reports, we detailed the use of stents in 20%
f femoropopliteal interventions4; in essence, a highly se-
ective posture for stenting has been our practice. The data
eported herein support selective stenting in most cases, yet
n patients with TASC II C & D lesions, there may be a
ong-term benefit of routine stenting. More data are
eeded to determine whether superior long-term primary
atency for these complex lesions could translate into bet-
er clinical outcomes.
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